ATE556323T1 - Neurofibrilläre marker - Google Patents

Neurofibrilläre marker

Info

Publication number
ATE556323T1
ATE556323T1 AT02720102T AT02720102T ATE556323T1 AT E556323 T1 ATE556323 T1 AT E556323T1 AT 02720102 T AT02720102 T AT 02720102T AT 02720102 T AT02720102 T AT 02720102T AT E556323 T1 ATE556323 T1 AT E556323T1
Authority
AT
Austria
Prior art keywords
tau
tau protein
derivative
agent
binding
Prior art date
Application number
AT02720102T
Other languages
English (en)
Inventor
Claude Wischik
Charles Harrington
Janet Rickard
David Horsley
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Application granted granted Critical
Publication of ATE556323T1 publication Critical patent/ATE556323T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
AT02720102T 2001-03-20 2002-03-20 Neurofibrilläre marker ATE556323T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106953.3A GB0106953D0 (en) 2001-03-20 2001-03-20 Neufofibrillary labels
PCT/GB2002/001318 WO2002075318A2 (en) 2001-03-20 2002-03-20 Neurofibrillary labels

Publications (1)

Publication Number Publication Date
ATE556323T1 true ATE556323T1 (de) 2012-05-15

Family

ID=9911161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720102T ATE556323T1 (de) 2001-03-20 2002-03-20 Neurofibrilläre marker

Country Status (13)

Country Link
US (3) US7335652B2 (de)
EP (1) EP1421389B1 (de)
JP (2) JP4288073B2 (de)
CN (2) CN101696977B (de)
AT (1) ATE556323T1 (de)
AU (1) AU2002251172B2 (de)
CA (1) CA2440794C (de)
DK (1) DK1421389T3 (de)
ES (1) ES2386773T3 (de)
GB (1) GB0106953D0 (de)
HK (1) HK1062044A1 (de)
PT (1) PT1421389E (de)
WO (1) WO2002075318A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
EP1643994A4 (de) * 2003-06-19 2010-09-08 Neuronautics Inc Verfahren zur hemmung oder umkehr von tau-filament-fibrillisierung
GB0322756D0 (en) * 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
JP5186212B2 (ja) 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
CN101460222B (zh) * 2006-03-29 2013-12-04 维斯塔实验室有限公司 锍化合物及其用途
CN103735554B (zh) 2006-03-29 2018-03-20 维斯塔实验室有限公司 蛋白聚集抑制剂
JP5132090B2 (ja) * 2006-06-16 2013-01-30 東和薬品株式会社 塩酸エピナスチンドライシロップ剤
CN101511803B (zh) 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
EP2954932B1 (de) 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Therapeutische verwendung von diaminophenothiazinen
EP2268314A2 (de) * 2008-03-21 2011-01-05 Adlyfe, Inc. Verwendung von pyrol zum befördern von peptiden durch die blut-gehirn-schranke
WO2009117042A1 (en) * 2008-03-21 2009-09-24 Adlyfe, Inc. Use of pyrene to carry non-peptide agents across the blood brain barrier
RU2518892C2 (ru) * 2008-09-23 2014-06-10 Виста Лабораториз Лтд. Лиганды для агрегированных молекул тау-белка
CN102307878B (zh) 2008-12-10 2014-10-15 维斯塔实验室有限公司 3，6-二取代的呫吨鎓盐
WO2010067085A2 (en) 2008-12-12 2010-06-17 Wista Laboratories Ltd. Synthesis of 9-(arylalkyl)-1,2,3,4-tetrahydro-υ-carboline and analogues and intermediates
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
SI2430007T1 (sl) 2009-05-12 2014-05-30 Wista Laboratories Ltd. Postopki kemijske sinteze diaminofenotiazinijevih spojin, ki vključujejo uporabo persulfatnih oksidantov
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
WO2011137447A1 (en) 2010-04-30 2011-11-03 Prostetta Antiviral Inc. Antiviral compounds
CN103209695A (zh) 2010-09-15 2013-07-17 弗·哈夫曼-拉罗切有限公司 氮杂苯并噻唑化合物、组合物及应用方法
CN103298789A (zh) * 2010-11-16 2013-09-11 通用电气健康护理有限公司 作为τ蛋白病理成像探针的杂环化合物
CA2818068C (en) 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
SI2673266T1 (sl) 2011-02-11 2016-11-30 Wista Laboratories Ltd. Fenotiazin diaminijeve soli in njihova uporaba
WO2013036749A1 (en) * 2011-09-07 2013-03-14 University Of Kansas Hcv helicase inhibitors and methods of use thereof
CN102942537B (zh) * 2012-11-09 2014-07-02 浙江大学 一种用作pH荧光探针的苯并噻唑-苯胺类化合物及其制备方法
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US10765755B1 (en) 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
SG11201604618TA (en) 2013-12-19 2016-07-28 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
CN107163022B (zh) * 2016-03-07 2021-07-16 上海如絮生物科技有限公司 一种异喹啉类化合物、其中间体、制备方法和应用
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
SE1750924A1 (sv) * 2017-07-14 2018-10-02 A method for analyzing the 3d structure of biomolecules
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
US11155609B2 (en) 2019-04-05 2021-10-26 TauC3 Biologies Limited Anti-TAUC3 antibodies and uses thereof
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
KR20220119094A (ko) 2019-12-19 2022-08-26 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
GB202010620D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd System
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
WO2023135200A1 (en) 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
CA1302250C (en) * 1986-04-04 1992-06-02 Khalid Iqbal Diagnostic for alzheimer's disease
EP0287909B1 (de) * 1987-04-08 1992-09-02 Salutar, Inc. Nachweis für Amyloidose und Alzheimer'sche Krankheit sowie Reagens hierfür
US5008099A (en) * 1987-04-08 1991-04-16 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
GB8724412D0 (en) 1987-10-19 1987-11-25 Medical Res Council Protein
FI101344B1 (fi) * 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
KR100231226B1 (ko) 1991-07-10 1999-11-15 스프레이그 로버트 월터 발수 처리용 및 발유 처리용 플루오로케미칼 조성물
EP0600951A4 (en) * 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
CA2125298A1 (en) 1991-12-06 1993-06-10 Eva-Maria Mandelkow Tools for the diagnosis and treatment of alzheimer's disease
WO1993019143A1 (en) * 1992-03-17 1993-09-30 Lord Corporation Colorant-containing electrorheological materials
US5536761A (en) 1992-12-07 1996-07-16 Sakura Color Products Corporation Water base dye ink composition
GB9317193D0 (en) 1993-08-18 1993-10-06 Zeneca Ltd Method
CA2196529A1 (en) * 1994-08-08 1996-02-22 Peter Davies Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5697985A (en) * 1995-06-07 1997-12-16 Bayer Corporation Process for the preparation storage-stable dye dispersions
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
JP2000344685A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
JP2000344684A (ja) 1999-03-26 2000-12-12 Bf Kenkyusho:Kk ピロニンｂ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
EP1048302A3 (de) * 1999-04-30 2002-07-17 Pfizer Products Inc. Radiotracer zur Untersuchung von Acetylcholinesterase und Alzheimer Erkrankung
AU2001244549A1 (en) 2000-03-22 2001-10-03 Bf Research Institute, Inc. Azure a analogues useful as probes in the diagnostic imaging for diseases due toaccumulation of amyloid and compositions for diagnostic imaging containing the analogues
PL215711B1 (pl) 2000-08-24 2014-01-31 Univ Pittsburgh Nowe zwiazki pochodne tioflawiny, sposób syntezy zwiazków i ich zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazki i zastosowanie kompozycji
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
US6953974B2 (en) * 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)

Also Published As

Publication number Publication date
US20080219929A1 (en) 2008-09-11
JP2004537034A (ja) 2004-12-09
CN101696977A (zh) 2010-04-21
CA2440794A1 (en) 2002-09-26
JP4288073B2 (ja) 2009-07-01
US20040213736A1 (en) 2004-10-28
EP1421389A2 (de) 2004-05-26
US8097615B2 (en) 2012-01-17
CA2440794C (en) 2012-05-01
WO2002075318A2 (en) 2002-09-26
EP1421389B1 (de) 2012-05-02
AU2002251172B2 (en) 2007-12-06
PT1421389E (pt) 2012-07-10
US20100285605A1 (en) 2010-11-11
WO2002075318A3 (en) 2004-03-11
GB0106953D0 (en) 2001-05-09
DK1421389T3 (da) 2012-08-13
CN101696977B (zh) 2014-02-19
ES2386773T3 (es) 2012-08-30
JP2009035566A (ja) 2009-02-19
HK1062044A1 (en) 2004-10-15
US7713962B2 (en) 2010-05-11
CN1578910A (zh) 2005-02-09
US7335652B2 (en) 2008-02-26

Similar Documents

Publication Publication Date Title
ATE556323T1 (de) Neurofibrilläre marker
DE69838748D1 (de) Feststellung molekularer interaktionen durch marker-untereinheiten-komplementation
ATE483825T1 (de) Zusammensetzungen für die identifizierung von adenoviren
DE602004019812D1 (de) Marker für neuromyelitis optica
WO2005114219A3 (en) Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
IL176479A0 (en) Methods and compositions for identifying rna-binding proteins
DE60223063D1 (de) C-kit inhibitoren
WO2004067728A3 (en) Methods and systems for the identification of rna regulatory sequences and compounds that modulate their function
WO2002027031A3 (en) Methods and reagents for live-cell gene expression quantification
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
AU2002239882A1 (en) Method for identifying a ligand for a biological substrate
DE602004015953D1 (de) Festphase immunochromatographische testverfahren
DK1246945T3 (da) Fremgangsmåde til identifikation af en mærkning anbragt på et fast legeme
DK2005190T4 (da) Inhibering af GASC1
WO2005033330A3 (en) Fluorescent probes for use in protein kinase inhibitor binding assay
WO2005036169A3 (en) Fluorescent probes for ribosomes and method of use
DK1236047T3 (da) Fluorescenskorrelationsspektroskopi til identifikation af forbindelse-mål-binding
HK1070694A1 (en) Identification of a compound capable of binding to hdrr or capable of modulating hdrr activity using a epf receptor, and isolation of hdrr
WO2004047615A3 (en) Hemiasterlin affinity probes and their uses
ATE452987T1 (de) Verfahren zur erkennung von zielen
NO20061215L (no) Fremgangsmate for identifisering av IRS-proteinkinase-inbibitorer eller -agonister
WO2002014545A3 (en) Method for determining weather a test compound binds to a large rna target
ATE461290T1 (de) Verfahren zur identifizierung von aktivestellen- proteasinaktivatoren
MY148511A (en) Neurofibrillary labels
MXPA02011513A (es) Metodo para identificar sustancias activas, valiosas para uso medico.